Healthcare PharmaceuticalsRoche's anti-CD20 biologic therapy (ocrelizumab) for multiple sclerosis, FDA approved March 28, 2017, as the first and only treatment approved for both relapsing and primary progressive MS. Subcutaneous formulation (Ocrevus Zunovo) approved September 2024. Ocrevus generated CHF 7.0 billion in 2025 sales, making it Roche's highest-selling pharmaceutical product.
multiple-sclerosisocrelizumabanti-cd20